PARP1 and cancer: PARP-1 activity was decreased in both cancers across all treatments with cleaved PARP-1 in HT29-treated cells significantly increasing following PtIIPHENSS, PtII5MESS, PtII56MESS, PtIV5MESS(OH)2 and PtIV56MESS(OH)2 treatment.